ISRG stock forecast, quote, news & analysis
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery... Show more
Why Intuitive Surgical (ISRG) Is Down -1.9% in the Last 30 Days
Key Takeaways
- ISRG stock declined -1.9% over the past 30 days amid FDA scrutiny on its stapler products and analyst price target reductions ahead of Q1 earnings.
- Over the past quarter, shares fell -10%, driven primarily by disappointing 2026 procedure growth guidance following Q4 earnings and increased competitive pressures in China.
- Key factors include regulatory headwinds, such as an FDA recall notice for curved-tip staplers, softer guidance, and macroeconomic influences on healthcare spending.
- Volatile trading with a 30-day low of $448 and high of $489 reflects market sensitivity to pre-earnings news and regional challenges.
- Positive notes include ongoing da Vinci system expansions in Europe, but these have not offset broader pressures.
Intuitive Surgical (ISRG) Company Overview and Market Position
Intuitive Surgical, Inc. (ISRG) is a global leader in robotic-assisted minimally invasive surgery. The company develops, manufactures, and markets the da Vinci surgical system, a platform that enables surgeons to perform complex procedures with enhanced precision, control, and visualization. Its core business model relies on an initial sale or lease of da Vinci systems to hospitals, followed by recurring revenue from instruments, accessories, and services required for each procedure.
Operating in the medical devices industry, Intuitive holds a dominant position in the robotic surgery market, particularly in the U.S., with a growing global footprint. Its strong fundamentals, including a large installed base of systems driving procedure growth and high barriers to entry due to its proprietary technology ecosystem, provide resilience. However, recent stock price movements reflect exposure to regulatory risks and international competition, which have pressured sentiment despite robust procedure demand.
Intuitive Surgical (ISRG) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ISRG stock declined -1.9%, closing at $469.21 on April 17 from $478.04 around March 21. The movement was volatile and range-bound, with a low of $448.17 on March 13 and a high of $489.00 on March 23, reflecting choppy trading amid news flow.
In the past quarter, shares dropped -10%, from $523.69 around January 21 to the recent $469.21 close. The trend was downward overall, starting from a January high near $586 before a sustained decline, marked by increased volatility including a March low of $448. This period showed a clear bearish shift after early-year peaks.
What Drove ISRG Stock Price in the Last 30 Days
The modest -1.9% decline in ISRG's stock price over the past 30 days stemmed from heightened regulatory scrutiny and analyst caution. In late March, news of an FDA recall and safety concerns over the company's curved-tip stapler contributed to a sharp 5% drop, pushing shares to a monthly low. This issue placed Q1 2026 results under focus, as investors weighed potential impacts on procedure volumes.
Additionally, competitive pressures in China intensified, with provincial tenders favoring local robotic surgery providers and increasing pricing demands on Intuitive's systems. Several analysts lowered price targets, including Mizuho to $525, BTIG to $574, and Truist to $580, citing these headwinds and CMS payment rule changes. Pre-earnings sentiment shifted negatively, leading to range-bound volatility despite some recovery attempts.
What Drove ISRG Stock Performance Over the Last Quarter
The -10% quarterly drop was anchored by Intuitive Surgical's Q4 2025 earnings on January 22, which beat expectations with EPS of $2.53 (versus $2.27 expected) and revenue of $2.87 billion (versus $2.75 billion). However, 2026 guidance for 13-15% procedure growth—down from 18% in 2025—disappointed investors, triggering an initial sell-off from January highs around $586.
Regulatory and competitive challenges compounded the pressure, including the March FDA stapler recall and ongoing China market share erosion from local rivals. Macroeconomic factors, such as healthcare reimbursement dynamics and broader medical device sector trends, added to the downward momentum. Institutional behavior shifted toward caution, with the stock underperforming the S&P 500 amid these sustained narratives.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI-driven trading bots from its extensive library of hundreds of algorithms actively trading thousands of tickers across various markets. These curated bots are selected based on recent performance metrics, relevance to current market conditions, and strategy effectiveness, highlighting only the most promising ones for user consideration. Strategies range from momentum and mean reversion to pattern recognition, spanning short-term day trades to longer-term swings, with transparent backtested and live results including win rates, profit factors, and drawdowns. This section helps investors explore automated trading without building their own systems. Check out the Trending AI Robots to see which ones align with your portfolio goals.
ISRG Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Q1 2026 earnings on April 21, expected to show revenue growth of 16% to $2.61 billion and EPS of $2.08, for updates on procedure volumes and guidance refinements. Ongoing FDA interactions regarding stapler safety and broader regulatory approvals for da Vinci enhancements will influence sentiment. In China, tender outcomes and local competition dynamics remain critical, alongside global procedure adoption trends and installed base expansions like recent European investments. Macro factors such as reimbursement policies (e.g., CMS FY27 rules), healthcare demand amid aging populations (the "Silver Tsunami"), and interest rate impacts on medtech valuations are key. Potential risks include further pricing pressures or supply chain issues, while catalysts could emerge from new indications or partnerships.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
ISRG in upward trend: price may jump up because it broke its lower Bollinger Band on June 02, 2026
ISRG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 38 cases where ISRG's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ISRG's RSI Oscillator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 50 cases where ISRG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ISRG just turned positive on June 08, 2026. Looking at past instances where ISRG's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in of 333 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ISRG as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ISRG entered a downward trend on June 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ISRG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.368) is normal, around the industry mean (4.530). P/E Ratio (50.170) is within average values for comparable stocks, (183.510). Projected Growth (PEG Ratio) (2.165) is also within normal values, averaging (3.448). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (14.104) is also within normal values, averaging (73.316).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of robotic technologies used for surgeries
Industry PharmaceuticalsOther